Eleison Pharmaceuticals Inc. (ELSN)

Eleison Pharmaceuticals will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Company Description

Eleison Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to acquiring, developing and commercializing late-stage therapies (in Phase II or Phase III trials) to treat rare, life-threatening diseases, such as pancreatic cancer, small cell lung cancer, pediatric bone cancer and brain cancer.

Our current portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD).

Each has received Orphan Drug Designation by the FDA, and glufosfamide and ILC have received Orphan Drug Designation by the EMA as well.

Each of the oncology indications we have targeted are characterized by significant unmet medical needs, that is, indications with a poor prognosis and low five year survival.

Our lead program, glufosfamide, is in development for pancreatic cancer, the third leading cause of cancer deaths in the United States according to the American Cancer Society.

Our ongoing pivotal Phase III study for glufosfamide in second-line pancreatic cancer is expected to be completed in 2023 with an NDA filing, with the FDA projected for 2024.

Eleison Pharmaceuticals Inc.
Country United States
Founded 2009
Industry Health Care
Sector Biotechnology
Employees 2
CEO Edwin J. Thomas

Contact Details

100 Overlook Center, 2nd Floor
Princeton, NJ 08540
United States
Phone (215) 554-3530
Website eleison-pharma.com

Stock Details

Ticker Symbol ELSN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001880047
Employer ID 45-4373885
SIC Code 2834

Key Executives

Name Position
Edwin J. Thomas Chief Executive Officer, President and Chairman of the Board
Keith Darragh, CPA, CGMA Chief Financial Officer and Secretary
Michael E. Lusty Vice President – Chemistry Manufacture and Contracts
Patrick Maguire, MD, PhD Chief Medical Officer
Matthew Allen Cromie Vice President – Clinical Research
Joel Morganroth, MD Director
Michael J. Otto, PhD Director
Frank Seidman Director
Bryan R. Wood Director

Latest SEC Filings

Date Type Title
Sep 19, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Sep 14, 2022 D Notice of Exempt Offering of Securities
Feb 23, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jan 24, 2022 S-1 General form for registration of securities under the Securities Act of 1933
Dec 13, 2021 DRS [Cover] Draft Registration Statement